-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 PLRtq0QSg31nvQ8ByUMn0+DvFI0kSdqJu+HQuwLgC2lQwXRGOIVaOyVpLYBrMZ9r
 Vuo2OCZTXWcewMQqQWm5dA==

<SEC-DOCUMENT>0001130319-07-000059.txt : 20070206
<SEC-HEADER>0001130319-07-000059.hdr.sgml : 20070206
<ACCEPTANCE-DATETIME>20070206173101
ACCESSION NUMBER:		0001130319-07-000059
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070206
FILED AS OF DATE:		20070206
DATE AS OF CHANGE:		20070206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		07585489

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>o34670e6vk.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e6vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>Form&nbsp;6-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>Report of Foreign Private Issuer</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>Pursuant to Rule&nbsp;13a-16 or 15d-16<BR>
of the Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>For the month of February&nbsp;2007<BR>
Commission File Number 000-31062</B></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>Oncolytics Biotech Inc.</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><I>(Translation of registrant&#146;s name into English)</I></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Suite&nbsp;210, 1167 Kensington Crescent NW<BR>
Calgary, Alberta, Canada T2N 1X7</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><I>(Address of principal executive offices)</I></DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Indicate by check mark whether the registrant files or will file annual reports under cover Form
20-F or </B><B>Form 40-F</B><B>.</B>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Form&nbsp;20-F <FONT face="Wingdings">&#111;</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Form&nbsp;40-F <FONT face="Wingdings">&#254;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Indicate by check mark if the registrant is submitting the </B><B>Form 6-K</B><B> in paper as permitted by
Regulation&nbsp;S-T Rule&nbsp;</B><B>101(b)(1)</B><B>: </B><FONT face="Wingdings">&#111;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Indicate by check mark if the registrant is submitting the </B><B>Form 6-K</B><B> in paper as permitted by
Regulation&nbsp;S-T Rule&nbsp;</B><B>101(b)(7)</B><B>: </B><FONT face="Wingdings">&#111;</FONT>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Note: </B>Regulation&nbsp;S-T Rule&nbsp;101(b)(7) only permits the submission in paper of a Form 6-K if submitted
to furnish a report or other document that the registrant foreign private issuer must furnish and
make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled
or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country
exchange on which the registrant&#146;s securities are traded, as long as the report or other document
is not a press release, is not required to be and has not been distributed to the registrant&#146;s
security holders, and, if discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Indicate by check mark whether by furnishing the information contained in this Form, the registrant
is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-</B><B>2(b)</B><B> under the
Securities Exchange Act of 1934.</B>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="85%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="50%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="45%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Yes <FONT face="Wingdings">&#111;</FONT>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">No <FONT face="Wingdings">&#254;</FONT></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant in connection with
Rule&nbsp;12g3-</B><B>2(b)</B><B>: 82 -</B>
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>






<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<!-- link1 "SIGNATURES" -->

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>Oncolytics Biotech Inc.</B><BR>
(Registrant)<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Date: February 6, 2007&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Doug Ball
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Doug Ball&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>


<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="70%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><IMG src="o34670o3467000.gif" alt="(ONCOLYTICS LOGO)"></DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">210,1167 Kensington Cr. N.W.<BR>
Calgary, Alberta <BR>
Canada T2N 1X7</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<HR noshade size="2" width="100%" align="center">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Oncolytics Biotech Inc. Announces Public Offering</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>Calgary, AB </B>&#151; <B>February&nbsp;5, 2007 </B>&#151; Oncolytics Biotech
Inc. (&#147;Oncolytics&#148;) (TSX:ONC; NASDAQ:ONCY) announced today that it has filed a preliminary short
form prospectus with Canadian securities regulators and a related registration statement with the
U.S. Securities and Exchange Commission under the U.S.-Canada multi-jurisdictional disclosure
system, relating to a proposed public offering of units. Each unit will be composed of one common
share and one-half of one common share purchase warrant. The number of units to be distributed and
the price of each unit will be determined in the context of the market with final terms to be
determined at the time of pricing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The net proceeds from this offering will be used by Oncolytics for its clinical trial program,
manufacturing activities in support of the clinical trial program and for the company&#146;s general
corporate purposes. The offering is expected to close on or about February&nbsp;22, 2007 and is subject
to the receipt of all necessary regulatory and stock exchange approvals.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">A preliminary short form prospectus relating to the units has been filed in the provinces of
British Columbia, Alberta, Manitoba and Ontario, and a registration statement under the U.S.-
Canada multi-jurisdictional disclosure system has been filed with the U.S. Securities and Exchange
Commission, but has not yet become effective. These securities may not be sold nor may offers to
buy be accepted prior to the time the registration statement becomes effective. This press release
shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any
sale of these securities in any state or province in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the securities laws of any such state or
province. No offer to buy the securities can be accepted and no part of the purchase price can be
received until the registration statement has become effective, and any such offer may be withdrawn
or revoked, without obligation or commitment of any kind, at any time prior to the notice of its
acceptance given after the effective date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Canaccord Capital Corporation is acting as lead manager on the offering. A copy of the
preliminary short form prospectus may be obtained from Canaccord Capital Corporation
&#151; in Canada, call 416-869-7708, in the U.S., call 1-617-788-1554, or send requests to:
Attention: Lee Ward, P.O. Box 516, 161 Bay Street, Suite&nbsp;3000, Toronto, Ontario M5J 2S1 (fax
requests &#151; 416-869-7708).
</DIV>

<DIV align="left" style="font-size: 8pt; margin-top: 6pt"><I>This press release contains forward-looking statements, within the meaning of Section
21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements,
including the Company&#146;s expectations related to the placement of the units, as to progress in the
clinical trial program and the Company&#146;s belief as to the potential of REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> <I>as a cancer therapeutic, involve known and
unknown risk and uncertainties, which could cause the Company&#146;s actual results to differ materially
from those in the forward-looking statements. Such risks and uncertainties include, among others,
ability of the Company to complete the offering on the terms set forth in its agreements, the
Company&#146;s ability to obtain regulatory approval for the offering, the availability of funds and
resources to pursue Research and Development projects, the efficacy
of</I></DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 8pt; margin-top: 6pt"><I>REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> <I>as a cancer treatment, the success and timely completion of clinical studies and
trials, the Company&#146;s ability to successfully commercialize REOLYSIN</I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP><I>, uncertainties related to
the research and development of pharmaceuticals, uncertainties related to the regulatory process
and general changes to the economic environment. Investors should consult the Company&#146;s quarterly
and annual filings with the Canadian and U.S. securities commissions for additional information on
risks and uncertainties relating to the forward looking statements. Investors are cautioned against
placing undue reliance on forward-looking statements. The Company does not undertake to update
these forward-looking statements, except as may be required pursuant to applicable securities laws.</I>
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="5" valign="top" align="left"><B>FOR FURTHER INFORMATION PLEASE CONTACT:</B></TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Oncolytics Biotech Inc.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Equicom Group
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">The Investor Relations Group</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Cathy Ward
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nick Hurst
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Erika Moran</TD>
</TR>
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">210, 1167 Kensington Cr NW
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">600, 205 5<SUP style="font-size: 85%; vertical-align: text-top">th</SUP> Ave. SW
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">11 Stone St, 3rd Floor</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Calgary, Alberta T2N 1X7
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Calgary, Alberta T2P 2V7
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">New York, NY 10004</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Tel: 403.670.7377
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: 403.538.4845
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Tel: 212.825.3210</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Fax: 403.283.0858
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 403.266.2453
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Fax: 212.825.3229</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><U>cathy.ward@oncolytics.ca</U>
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><U>nhurst@equicomgroup.com</U>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top"><U>emoran@investorrelationsgroup.com</U></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>o34670o3467000.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 o34670o3467000.gif
M1TE&.#EAY@`[`/<```````@("!`0$!@8&"$A(2DI*3$Q,3DY.4)"0DI*2E)2
M4EI:6F-C8VMK:W-S<WM[>X2$A(R,C)R<G*6EI:VMK;6UM;V]O<[.SM[>WN?G
MY^_O[_?W]___________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________RP`````Y@`[```(_@`Y"!Q(L*#!@P@3*ES(L*'#
MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ERTQP)Q)LZ;-
MFSASZMS)LZ?/GT"#@M1@04$"!@F,+H!PX8+0IU`I8J"@H``"`@<06"5``,$`
M`P8:2-`0M:Q9@P^X)OW*54!;K6`3('A@X:S=IQ@>('`KX("""60-2H![E4`#
MIW<3[ZQ`P,"!!0XJ!%XXP4%6!4L5:ZZIX8$"`P@62"2*`('<!IM3NU1`0"Z%
M#!0[$UA0@('JVRC3)C`@TZ(&#`,8+%"`N[A(#*$9],:8H8%PV\:C;\1@%`%B
MC1>Z-D`MO;M%TPB6_F^D<-0`;._H(5H0P,`!2`:AN:>?OU"!A`23.VK8;4`"
M_?\'76!``A"(=`$"#!`'X(("8::`>!\M8(`"UZ&D084,KJ0!`@?X-]*&V[&4
M7X8J53"@AR.5!AV)Z24W(DB>+8`ABST1]>)##(18$F.M':1!!!&,99`%#3B`
M(D(7%+E=>Q?\YB,'/Q;)@'`/0%B0@`E,L)!G1]VH`6;6";2?40I\=E0!8#E&
M`(82</6`0AL.P)6<1DI@)0822""G6P<D0$$$%#Q400'VG61``>X9A$$`"!@0
M04$:2""``04BU!D`[,D5&J9'#E04II@=U0!K!TAV$'(%U`5G:0<T\.(#_F!5
MZ)QS4\[F0`0+/!"!`Q!*`-J;!UG`P`%@/0#!`Q(XP)Y@!$P*I+`1%.!6IPH=
M>("6)EDE'T$7##`J`=0B!:Q!V1$0`8886`EE`H:I.A`&$'"E'+D&+%!!0ZP5
M$,%Y4%I00`$S$H1<APL-EL"X!%F@UHV""=``PA5=4!NU(=6[HL`%'!!!59TV
MD$"B`Y&E`;$0KTK`O`?!ZNB0"#3@[D*C(N"A!A2T%K#`"C!`,4$2*&"L011P
MR`##0SK0,M&"RH5M2:!M^RZQ&9C6'T$/+/"H00@NH"Y"_C)0<LA&E1RU`4LS
M9+1P&3R`9ME(%K#`S@/==Y1![<W]$*Y6.?!`_@469(`TUQS"[5&](`N<E$RD
M1A#8L(4+9$%8#=SK$)A;<X#<<.BV_#)#@QV`E,P-(9>`X!P,ID#C'!SJP,W5
M[F4``,TF8$'EP2)(^D8:3/@U!NSVML!P'F[G-`<6F';UY&[#G3L#`VR.JN0/
MZ39U0X^#6W!\!K7&P.8.:7`A!L,&H$!H#Q7UMJ$)#,_!!0N$-]"9CWI<L@;P
M%4![01C4^[5`$L]%K@(NB\B7%A`HA^3O?)8J'8)*UH!&[2\B$F-``6XGD`P<
M130EP4!M$G"J`@Q@.18L#04@X`#U24@!!9R<7+96O>%=8'S<6\B&&'`\AF"@
M*Z3KF=X,,D`#L.XA_AEH'P)2R)"Y7$PD>E+`C<!'`/'D+RD?4]^&^C0_",ED
M0P5PE:(:I;['-8!M`J$=`B*@/B0)`($)D<"4RL@:`J7KC1:00`VAI)R^>2]=
M&G"``@(PQX4L8#=@C)!>;B0@WESICUHY(D$FD(``9(P_AP+`T`R2`0@,@%$&
MF%,!&-5'_H&%*P4`P"4#$(!*G:HKBDP(!@XP@$[R#)4)25(`+CD``#"*0_SB
M0`2RTJP!;+*6]0JD0HK7`"(.!7NGFD`#K$04"53`F)#"TP0H,$(*R*1RD6K*
MN3!@@1@F;';@!.</+=>4AQ!E=C+$P`6821`GP0E*!*&`-PW8,M1YY`'L_AHG
MC7!'DP8F0)^^$0X']YD>^@U').29R]\(FAH&S`9Z'CD`!%+)4..L\F,+E4A>
M.`1-;C7E?NMCR`70J9!I/G,"\]1`!28@QW%6(`(/R"6DL)4!.UDDC@IY`+8N
M8$^!18"&'Z$*?#+ZD+P,:Y((P8``8.HUHE%EF`GRU8,2TDV'6:"C`O%5-W\X
M@;"4DZKR`0`%$R+!A.1N`;:!E5E_YTJ-/*"$"LI(I#A$`!D*P%BM4@@950F`
MXT6@K@HAP`,]"9D'7B``(%W?;-(G`*PZ!"F!_1'9"J!*`4`4)"44#E'A!$4$
M_$T#`DB7!"2I*('\5*\4XB90%6*`P1*/0MW,U*FC(N78"YA2`&-%R+`BN[ZK
MF%5^\FSK3Q/KH^=@L")G;>`\WT6`\3W@AQ>@Z$!@VMJV3M>424U*@FAG@0B,
M<9X8X`YU+O)<A<C'`JY-E]=85Z7-\A`I$@0H#R_PL:/(]R5$=6_W](L2XDXD
M`A^3J#`/4E.YR,4!_.6)3"LJ$95Q29YF#9*W<C1&!C-X,(0*3:[RE*<)_#0K
M0CN8A4><.V(AP`%HQ0R*ER277-UWQ`OJV6Z2<B@TF08"_H7Q/C'P&[(T2<=`
1#K*0ATSD(AOYR$CF0$```#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
